Therapeutic implications of glucose transporters (GLUT) in cerebral ischemia

Neurochem Res. 2022 Aug;47(8):2173-2186. doi: 10.1007/s11064-022-03620-1. Epub 2022 May 21.

Abstract

Cerebral ischemia is a leading cause of death in the globe, with a large societal cost. Deprivation of blood flow, together with consequent glucose and oxygen shortage, activates a variety of pathways that result in permanent brain damage. As a result, ischemia raises energy demand, which is linked to significant alterations in brain energy metabolism. Even at the low glucose levels reported in plasma during ischemia, glucose transport activity may adjust to assure the supply of glucose to maintain normal cellular function. Glucose transporters in the brain are divided into two groups: sodium-independent glucose transporters (GLUTs) and sodium-dependent glucose cotransporters (SGLTs).This review assess the GLUT structure, expression, regulation, pathobiology of GLUT in cerebral ischemia and regulators of GLUT and it also provides the synopsis of the literature exploring the relationship between GLUT and the various downstream signalling pathways for e.g., AMP-activated protein kinase (AMPK), CREB (cAMP response element-binding protein), Hypoxia-inducible factor 1 (HIF)-1, Phosphatidylinositol 3-kinase (PI3-K), Mitogen-activated protein kinase (MAPK) and adenylate-uridylate-rich elements (AREs). Therefore, the aim of the present review was to elaborate the therapeutic implications of GLUT in the cerebral ischemia.

Keywords: Cerebral ischemia; GLUT-1 deficiency syndrome; Glucose transporters; Hypoxia-inducible factor 1; Neurodegeneration.

Publication types

  • Review

MeSH terms

  • Biological Transport
  • Brain Ischemia*
  • Glucose / metabolism
  • Glucose Transport Proteins, Facilitative* / metabolism
  • Humans
  • Sodium

Substances

  • Glucose Transport Proteins, Facilitative
  • Sodium
  • Glucose